AR056814A1 - Composiciones farmacéuticas - Google Patents

Composiciones farmacéuticas

Info

Publication number
AR056814A1
AR056814A1 ARP060105038A ARP060105038A AR056814A1 AR 056814 A1 AR056814 A1 AR 056814A1 AR P060105038 A ARP060105038 A AR P060105038A AR P060105038 A ARP060105038 A AR P060105038A AR 056814 A1 AR056814 A1 AR 056814A1
Authority
AR
Argentina
Prior art keywords
disorders
pharmaceutical composition
pharmaceutical compositions
thiazepine
dibenzo
Prior art date
Application number
ARP060105038A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR056814A1 publication Critical patent/AR056814A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion provee métodos de tratamiento con una composicion farmacéutica, más particularmente una composicion farmacéutica de liberacion sostenida, que comprende 11-[4-[2-(2-hidroxietoxi)etil]-1-piperazinil]dibenzo-[b,f][1,4]tiazepina o una sal farmacéuticamente aceptable de la misma, así como también nuevos y mejorados métodos para tratar una variedad de trastornos y afecciones psicologicos que incluyen, pero que no se limitan a, Trastornos del Estado de ánimo y Trastornos de Ansiedad y para tratar uno o más de los síntomas de estos trastornos.
ARP060105038A 2005-11-18 2006-11-16 Composiciones farmacéuticas AR056814A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73794305P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
AR056814A1 true AR056814A1 (es) 2007-10-24

Family

ID=38048902

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105038A AR056814A1 (es) 2005-11-18 2006-11-16 Composiciones farmacéuticas

Country Status (8)

Country Link
US (2) US20070185080A1 (es)
EP (1) EP1951256A1 (es)
JP (1) JP2009515952A (es)
CN (1) CN101360504A (es)
AR (1) AR056814A1 (es)
TW (1) TW200735878A (es)
UY (1) UY29924A1 (es)
WO (1) WO2007058593A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1976487A2 (en) * 2006-01-25 2008-10-08 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
WO2009082268A2 (ru) 2007-12-21 2009-07-02 Alla Chem, Llc ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
EP2268283A2 (en) * 2008-03-12 2011-01-05 Dexcel Ltd. Oral modified-release formulations containing thiazepines
DK2285357T3 (da) * 2008-05-30 2014-06-02 Ucb Pharma Sa Farmaceutisk sammensætning omfattende brivaracetam
CN101912374B (zh) * 2010-08-08 2016-01-20 浙江华海药业股份有限公司 喹硫平缓释片及其制备方法
CA2834713A1 (en) * 2010-12-03 2012-06-07 Anthony Alexander Mckinney Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters
CN102525988B (zh) * 2011-01-04 2016-01-06 北京天衡药物研究院 富马酸喹硫平缓释片
CN102218042A (zh) * 2011-05-26 2011-10-19 青岛黄海制药有限责任公司 富马酸喹硫平组合物的缓释片剂及其制备方法
CN104586805A (zh) * 2014-07-08 2015-05-06 上海中西三维药业有限公司 富马酸喹硫平缓释片剂及其制备方法
WO2018204935A1 (en) 2017-05-05 2018-11-08 Canary Speech, LLC Medical assessment based on voice
US20200188358A1 (en) * 2018-12-14 2020-06-18 Praxis Precision Medicines, Inc. Methods for the treatment of depression
MX2022004654A (es) * 2019-10-17 2022-08-15 Hercules Llc Una composición dispersable de liberación prolongada, y un proceso para la elaboración de la misma.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
AU2003268026A1 (en) * 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic

Also Published As

Publication number Publication date
EP1951256A1 (en) 2008-08-06
US20070185080A1 (en) 2007-08-09
WO2007058593A1 (en) 2007-05-24
UY29924A1 (es) 2007-06-29
JP2009515952A (ja) 2009-04-16
US20110319384A1 (en) 2011-12-29
TW200735878A (en) 2007-10-01
CN101360504A (zh) 2009-02-04

Similar Documents

Publication Publication Date Title
AR056814A1 (es) Composiciones farmacéuticas
ECSP088499A (es) Nuevos compuestos de 2-amino-imidazol-4-ona y su uso en la fabricación de un medicamento para uso en el tratamiento de alteración cognitiva, enfermedad de alzheimer, neurodegeneración y demencia
UY30414A1 (es) Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones.
BRPI0412909A (pt) uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer
CR7785A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
SV2008002511A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
PA8493701A1 (es) Compuestos para tratar la obesidad
ECSP10010035A (es) Amidas heterocíclicas y sus métodos de uso
ECSP088969A (es) Amino-imidazolones y su uso como medicamento para tratar deficiencias cognitivas, enfermedad de alzheimer, neurodegeneración y demencia
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
ES2674129T3 (es) Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento
UY30098A1 (es) Compuestos de tiazol y metodos de uso
UY32391A (es) Compuestos amino-heterocíclicos
CO6460766A2 (es) Compuestos de haloalquil heteroaril benzamida
UY29320A1 (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas, así como preparaciones farmacéuticas que las contienen
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
FR2901467B1 (fr) Prothese anatomique pour le traitement des hernies, telles que hernies inguinales et crurales et autres
NI200800253A (es) Tetrahidro-pirimidoazepinas como moduladores de trpv1
ECSP067019A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
ECSP066770A (es) Nuevos ésteres de quinuclidina cuaternizados

Legal Events

Date Code Title Description
FA Abandonment or withdrawal